Paricalcitol ( DrugBank: Paricalcitol )

4 diseases

ID	Disease name (Link within this page)	Number of trials
19	Lysosomal storage disease	1
66	IgA nephropathy	1
218	Alport syndrome	1
238	Vitamin D-resistant rickets	1

19. Lysosomal storage disease

Clinical trials : 854 / Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02090608 (ClinicalTrials.gov)	March 2012	14/3/2014	Paricalcitol in Fabry Disease		Fabry Disease;Proteinuria	Drug: Paricalcitol	Federico II University	NULL	Completed	18 Years	75 Years	Both	14	N/A	Italy

Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00599963 (ClinicalTrials.gov)	January 2008	2/1/2008	Paricalcitol for the Treatment of Immunoglobulin A Nephropathy	Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study	IgA Nephropathy	Drug: paricalcitol	Chinese University of Hong Kong	NULL	Withdrawn	18 Years	65 Years	Both	0	Phase 3	Hong Kong;China

Clinical trials : 26 / Drugs : 33 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 29

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02378805 (ClinicalTrials.gov)	July 1995	26/2/2015	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies	Thin Basement Membrane Disease;Familial Benign Hematuria;Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease	Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol	University Hospital Goettingen	Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine	Recruiting	N/A	N/A	All	500		Germany

Clinical trials : 29 / Drugs : 25 - (DrugBank : 11) / Drug target genes : 4 - Drug target pathways : 20

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00417612 (ClinicalTrials.gov)	January 2007	28/12/2006	Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets	The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH)	Hypophosphatemia, Familial;Hyperparathyroidism	Drug: Paricalcitol;Other: Placebo	Yale University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	9 Years	N/A	All	33	Phase 3	United States